Trial Profile
Phase 2 study of vadastuximab talirine in younger newly diagnosed acute myeloid leukemia patients
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Vadastuximab talirine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 27 Apr 2017 According to a Seattle Genetics media release, this trial is expected to start in second half of 2017.
- 10 Dec 2016 New trial record
- 03 Dec 2016 According to a Seattle Genetics media release, this trial is expected to start in 2017.